Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 12—December 2012
Peer Reviewed Report Available Online Only

Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010

Rebecca LipsitzComments to Author , Susan Garges, Rosemarie Aurigemma, Prasith Baccam, David D. Blaney, Allen C. Cheng, Bart J. Currie, David Dance, Jay E. Gee, Joseph Larsen, Direk Limmathurotsakul, Meredith G. Morrow, Robert Norton, Elizabeth O’Mara, Sharon J. Peacock, Nicki Pesik, L. Paige Rogers, Herbert P. Schweizer, Ivo Steinmetz, Gladys Tan, Patrick Tan, W. Joost Wiersinga, Vanaporn Wuthiekanun, and Theresa L. Smith
Author affiliations: Author affiliations: Department of Health and Human Services, Washington, DC, USA (R. Lipsitz, J. Larsen, L.P. Rogers); National Institutes of Health, Bethesda, Maryland, USA (S. Garges, R. Aurigemma); IEM, Research Triangle Park, North Carolina, USA (P. Baccam); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D. Blaney, J.E. Gee, M. Morrow, E. O’Mara, N. Pesik, T. Smith); Royal Darwin Hospital, Casuarina, Northern Territory, Australia (A. Cheng, B.J. Currie); Menzies School of Health Research, Casuarina, (A. Cheng, B.J. Currie); Monash University Melbourne, Victoria, Australia (A. Cheng); Alfred Hospital, Melbourne (A. Cheng); Mahosot Hospital, Vientiane, Laos (D. Dance); University of Oxford, Oxford, UK (D. Dance); Mahidol University, Bangkok, Thailand (D. Limmathurotsakul, S.J. Peacock, V. Wuthiekanun); Townsville Hospital, Townsville, Queensland, Australia (R. Norton); University of Cambridge, Cambridge, UK (S. Peacock); Colorado State University, Fort Collins, Colorado, USA (H.P. Schweizer); University of Greifswald, Greifswald, Germany (I. Steinmetz); DSO National Laboratories, Singapore (G. Tan); Genome Institute of Singapore, Singapore (P. Tan); Duke–National University of Singapore Graduate Medical School, Singapore (P. Tan); and Academic Medical Center, Amsterdam, the Netherlands (J. Wiersinga)

Main Article

Table 3

Workshop results for postexposure prophylaxis for Burkholderia pseudomallei and Bmallei infections during a public health emergency, 2010*

Drug Patient characteristics Recommended dosage/frequency
Trimethoprim/sulfamethoxazole Adult, >60 kg 160 mg/800 mg tablets: 2 tablets every 12 h
Adult, 40–60 kg 80 mg/400 mg tablets: 3 tablets every 12 h
Adult, <40 kg 160 mg/800 mg tablets: 1 tablet every 12 h OR
80 mg/400 mg tablets: 2 tablets every 12 h

8 mg/40 mg/kg; maximum dose 320 mg/1,600 mg every 12 h

Amoxicillin/clavulanic acid (co-amoxiclav)
Adult, >60 kg 500 mg/125 mg tablets: 3 tablets every 8 h†
Adult, <60 kg 500 mg/125 mg tablets: 2 tablets every 8 h†
Child 20 mg/5 mg/kg every 8 h; maximum dose 1,000 mg/250 mg every 8 h

*Duration of post-exposure prophylaxis is 21 d. If the organism is susceptible and the patient does not have a documented allergy to it, oral trimethoprim/sulfamethoxazole is the agent of first choice. If the organism is resistant to trimethoprim/sulfamethoxazole or the patient is intolerant, the second-line choice is co-amoxiclav.
†Weight-based dosage based on 20 mg/5 mg/kg/dose.

Main Article

Page created: November 06, 2012
Page updated: November 06, 2012
Page reviewed: November 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.